Delivery Order 75A50120D00016-75A50123F33005
- Not listed
- This is a federal contract award to Allucent Government Services (Us) LLC, a for-profit clinical research organization, by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS). The contract, which is a Delivery Order with a Cost Plus Fixed Fee pricing type, is for $2,065,280.00 and has an ultimate completion date of December 4, 2025. The contract is for "CLINICAL STUDIES NETWORK- CLINICAL TRIAL...
- On July 8, 2024, the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of Health and Human Services awarded a $4.04 million definitive contract to Allucent Government Services (US) LLC to support the D-COHRE Partnership, a research and development initiative designed to enhance innovation through decentralized care capabilities and execute more efficient clinical research. The contract, which carries a firm fixed price and no set-aside designation, is...
- This is a cost-plus-fixed-fee delivery order awarded to Allucent Government Services (US) LLC, a for-profit organization, by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). The award, valued at $92,583, is for the second year of base contract services under a larger $400 million IDIQ contract with ASPR for clinical trial planning and execution services, including support for ASPR's medical countermeasure programs. The...
- This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS). The award, with a ceiling value of $8,493,515.34, is for specimen collection services. The contract was awarded to Allucent Government Services (Us) LLC, a for-profit clinical research organization, and is a delivery order under a larger $400 million indefinite delivery vehicle (IDV) from ASPR for clinical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Task Order 75N93024F00001 to Allucent Government Services (US) LLC on August 15, 2024, under the Early Phase Clinical Trial Units (EPCTU) indefinite delivery vehicle. This delivery order, with a ceiling value of $3.2 million and an ultimate completion date of May 14, 2027, will be performed in Cary, North Carolina. The contract utilizes a cost-plus-fixed-fee pricing structure with no set-aside designation. Allucent,...
- The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a delivery order valued at $330.2 million to Icon Government and Public Health Solutions, Inc. on August 22, 2023, for clinical trial planning and execution services supporting next-generation COVID-19 vaccine development. The contract, which operates on a cost-plus-fixed-fee basis with an ultimate completion date of April 11, 2025, will be performed in...
- This federal contract award is for Task Order 75N93022F00001 under the Early Phase Clinical Trial Units (EPCTU) Indefinite Delivery/Indefinite Quantity (IDIQ) contract, which was awarded to Allucent Government Services (Us) LLC, a for-profit clinical research organization. The task order has a ceiling value of $1,508,562.00 and a period of performance through January 13, 2032. The contract is a Cost Plus Fixed Fee type and was awarded by the National Institute of Allergy and Infectious...
- The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a delivery order valued at $34.5 million to Icon Government and Public Health Solutions, Inc. on September 27, 2023, for Clinical Trial Planning and Execution (CTPE) activities focused on H5 flu research. The contract, which carries a cost-plus-fixed-fee pricing structure with an ultimate completion date of July 31, 2026, is being performed in Hinckley, Ohio. This...
- This is a $16,382,387.80 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to PPD Development, LP. The contract is for clinical services described in Tasks 1 through 15 under the ASPR-16-05933 requirement, which is part of the Medical Countermeasures Clinical Studies Network IDIQ contract vehicle. The contract is for a Heterologous Prime Boost Influenza Vaccine Trial and does not have a set-aside...
- This is a $16,132,759.35 cost-plus-fixed-fee delivery order contract awarded to Rho Federal Systems Division Inc. by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract is part of the Medical Countermeasures Clinical Studies Network, an ASPR indefinite delivery/indefinite quantity (IDIQ) contract with a potential value of $250 million. Under this delivery order, Rho will provide a range of services including...
- 75A50120D00016Indefinite Delivery Contract
- 75A50120D00016-75A50123F33005Delivery Order
The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a delivery order valued at approximately $370 million to Allucent Government Services (US) LLC for clinical trial planning and execution in support of COVID next-generation vaccine development. The contract, awarded on August 22, 2023, with an ultimate completion date of April 11, 2025, operates under a Cost Plus Fixed Fee pricing structure with no set-aside designation. Work will be performed in Houston, Texas, where Allucent maintains its primary clinical research division. This delivery order is issued under ASPR's larger $550 million indefinite delivery vehicle for clinical trial planning and execution services, which serves as the contracting mechanism for multiple medical countermeasure programs supporting the federal government's public health preparedness initiatives. Allucent Government Services, formerly known as Pharm-Olam LLC, is a specialized clinical research organization with extensive expertise in comprehensive clinical trial support across the entire product development lifecycle, particularly for infectious disease research and medical countermeasure development. The company brings significant experience managing federal clinical trial programs, including previous major task orders from ASPR and contracts with the National Institutes of Health and Department of Defense. Through this award, Allucent will leverage its established capabilities in clinical trial planning, execution, subject matter expert consultation, and regulatory support to advance the development of next-generation COVID vaccines as part of the federal government's ongoing pandemic preparedness and response efforts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00008 | Other Administrative Action | $0 | 12/11/25 | |
| P00007 | Terminate for Convenience | $0 | 4/11/25 | |
| P00006 | Other Administrative Action | $0 | 3/5/25 | |
| P00005 | Supplemental Agreement for work within scope | $0 | 10/31/24 | |
| P00004 | Supplemental Agreement for work within scope | $26.8m | 9/24/24 |